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Identification of Protein Palmitoylation Inhibitors from a Scaffold 
Ranking Library 
Laura D. Hamel1, Brian J. Lenhart2, David A. Mitchell1, Radleigh G. Santos2, Marc A. Giulianotti2,3,4  
and Robert J. Deschenes*1,4 
1Department of Molecular Medicine, University of South Florida, Tampa, FL 33612, USA 
2Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987, USA 
3Department of Chemistry, University of South Florida, Tampa, FL 3362, USA 
4Center for Drug Discovery and Innovation, University of South Florida, FL 3362, USA 
Abstract: The addition of palmitoyl moieties to proteins regulates their membrane targeting, 
subcellular localization, and stability. Dysregulation of the enzymes which catalyzed the palmitoyl 
addition and/or the substrates of these enzymes have been linked to cancer, cardiovascular, and 
neurological disorders, implying these enzymes and substrates are valid targets for pharmaceutical 
intervention. However, current chemical modulators of zDHHC PAT enzymes lack specificity and affinity, underscoring 
the need for screening campaigns to identify new specific, high affinity modulators. This report describes a mixture based 
screening approach to identify inhibitors of Erf2 activity. Erf2 is the Saccharomyces cerevisiae PAT responsible for 
catalyzing the palmitoylation of Ras2, an ortholog of the human Ras oncogene proteins. A chemical library developed by 
the Torrey Pines Institute for Molecular Studies consists of more than 30 million compounds designed around 68 
molecular scaffolds that are systematically arranged into positional scanning and scaffold ranking formats. We have used 
this approach to identify and characterize several scaffold backbones and R-groups that reduce or eliminate the activity of 
Erf2 in vitro. Here, we present the analysis of one of the scaffold backbones, bis-cyclic piperazine. We identified 
compounds that inhibited Erf2 auto-palmitoylation activity using a fluorescence-based, coupled assay in a high throughput 
screening (HTS) format and validated the hits utilizing an orthogonal gel-based assay. Finally, we examined the effects of 
the compounds on cell growth in a yeast cell-based assay. Based on our results, we have identified specific, high affinity 
palmitoyl transferase inhibitors that will serve as a foundation for future compound design. 
Keywords: Acyltransferase, bis-cyclic piperazine, Erf2, enzyme inhibitor, high throughput screening (HTS), palmitoylation, 
zDHHC. 
1. INTRODUCTION 
 S-acylation is the enzymatic addition of a fatty acid 
(acyl) group onto one or more cysteine residues of a protein 
via a thioester linkage. The bulk of S-acylation involves the 
addition of a C16:0 carbon palmitoyl moiety and so we will 
refer to S-acylation as S-palmitoylation. A number of 
cellular processes involve the regulated addition of palmitate 
to proteins and includes signal transduction, protein turnover, 
vesicle fusion, and cell-cell interactions. At the protein level, 
the addition of palmitate enhances a protein’s membrane 
affinity as well as distribution in membrane micro-domains, 
mediates protein-protein interactions, trafficking, stability, 
and aggregation state [1]. While other protein lipidations, 
such as prenylation and myristoylation, are physiologically 
irreversible, the formation of the thioester linkage indicative 
of protein palmitoylation is reversible, and has led to a 
proposal that repeated rounds of acylation and de-acylation 
regulate substrate activity, localization and turn-over [2]. 
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MDC07, Tampa, FL 33612, USA; Tel: (813) 974-6393;  
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 A family of protein acyl transferases (PATs) catalyzes 
the addition of a palmitoyl moiety to proteins. Genes 
encoding members of the PAT family have been identified in 
all sequenced eukaryotic genomes. This family of enzymes 
catalyze palmitoylation by a two-step reaction [3-6]. The 
first step, autopalmitoylation, results in the formation of the 
enzyme-palmitoyl intermediate via a thioester linkage 
between palmitate, donated from palmitoyl-CoA, and the 
active site cysteine of the enzyme. The palmitoyl moiety is 
then transferred from the enzyme to a receiver cysteine of 
the protein substrate in the second step of the reaction. In the 
absence of a protein substrate, water attacks the active site 
causing hydrolysis of the enzyme-palmitoyl complex 
thioester linkage, thus regenerating the enzyme and 
producing palmitic acid [3, 4]. 
 Alterations in palmitoylation have been implicated in the 
etiology of cancer, cardiovascular disease, and neurological 
disorders [1, 7]. However, there are currently no drugs that 
target palmitoylation and the limited numbers of inhibitors 
that do exist exhibit low affinity and lack specificity. The 
most widely used inhibitor, 2-bromopalmitic acid (2-BP), is 
a non-metabolizable palmitate analog that elicits pleiotropic 
effects on cellular metabolism [8]. Despite a recent mass 
spectrometry study where its preference for palmitoylated 
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substrates or PAT enzymes was not detectable, 2-BP conti-
nues to be the primary experimental inhibitor of palmitoylat-
ion in part due to the lack of a more suitable alternative [9]. 
Furthermore, 2-BP also inhibits the depalmitoylating 
thioesterase, Apt1 [10]. Thus, the need to identify specific, 
high affinity inhibitors of protein palmitoylation is critical 
for the progression of palmitoylation research, and for the 
regulation of palmitoylation for therapeutic intervention. 
 We have recently described a high-throughput screening 
technique for quantifying autopalmitoylation and will be 
applying that assay to a screening campaign for inhibitors of 
palmitoylation from a unique compound scaffolding 
chemical library. This approach allows for the interrogation 
of millions of compounds with only hundreds of reactions 
[11-13]. In the present study, we describe the use of this 
assay for the identification of a unique class of compounds, 
based on a bis-cyclic piperazine scaffold that inhibits the 
autopalmitoylation activity of the yeast Ras PAT, Erf2. 
2. MATERIALS AND METHODS 
2.1. Strains, Media, and Yeast Techniques 
 Yeast growth media were prepared as described previously 
[14]. Cells were grown in synthetic complete (SC) medium or 
YPD (1% yeast extract, 2% peptone, and 2% glucose) medium 
[14]. Induction of GAL1, 10 promoters were achieved by adding 
4% galactose to SC medium in the absence of glucose. Yeast 
transformations were performed using the lithium acetate 
procedure [15]. Three yeast strains were used for this study: 
RJY1941 (S288C) MATα leu2-3,112 ura3-52 ade2 ade8 lys2 
ras1::HIS3 Ras2(CS-ext) erf2Δ::KANr erg6Δ::TRP1 [YCp52-
RAS2], RJY1942 (S288C) MATα leu2-3,112 ura3-52 ade2 ade8 
lys2 ras1::HIS3 Ras2(CS-ext) erf2Δ::KANr erg6Δ::TRP1 
[YCp52] and RJY1842 (MATa/α ade2-1/ade2-1 leu2-
3,112/leu2-3,112 ura3-52/ura3-52 trp1-1/trp1-1 his3-
11,15/his3-11,15 can1-100/can1-100 GAL+/GAL+ psi+/psi+ 
erf4Δ::NATr/erf4Δ::NATr [16]. 
2.2. Protein Purification 
 Strain RJY1842 was transformed with pESC(-Leu)-
6xHIS-Erf2-(Flag)-Erf4 and grown to 2 x 107 cells/ml in 
SC(-Leu) medium containing 2% (v/v) ethanol/ 2% (v/v) 
glycerol at 30°C with shaking. 50 mls (1x109 cells) were 
added to 1 liter of YEP medium supplemented with 4% 
galactose for induction. Cells were induced with shaking 
(230 RPM) for 18 hrs (30°C) and then harvested by 
centrifugation at 3000xg for 15 mins. The resulting pellet 
was resuspended in breaking buffer (50 mM Tris-Cl pH 8, 
500 ml NaCl, 1 mM EDTA, 1 mM DTT, 1xPIC, 8 µl/ml 
saturated PMSF/isopropyl alcohol), and the cells were lysed 
using glass beads (400-600 mesh, Sigma) for 40 mins with 1 
min pulses (1 min cooling). The resulting extract was spun at 
3000xg for 15 mins to remove cellular debris and unbroken 
cells, followed by a crude membrane fraction (P13) by 
centrifugation (13,000xg) for 0.5 hrs at 4°C. The supernatant 
was discarded and the pellet was resuspended in Tris 
buffered saline, pH 8, with the aid of a Dounce homogenizer. 
The resulting extract was adjusted to a final concentration of 
1% Triton-X100. To solubilize the membranes, the extract 
was incubated at 4°C (1.5 hrs). Insoluble material was then 
removed by centrifugation (13,000xg) for 0.5 hrs at 4°C. The 
supernatant was incubated with Ni-NTA resin at 4°C for 1 
hr. The resin was washed 3x with Solution W (50 mM Tris-
HCl, pH 8, 150 mM NaCl and 1% Triton-X100). The protein 
was eluted with 50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% 
Triton-X100, 5% glycerol and 250 mM imidazole. Eluates 
were desalted and concentrated using 50 mM Tris-Cl, pH 8, 
150 mM NaCl, 1% Triton-X100 and 5% glycerol. Fractions 
containing 6xHis-Erf2/FLAG-Erf4 were pooled to obtain 
approximately 0.2 mg of purified Ras PAT per liter of 
culture as determined by SDS-PAGE against a standard 
curve of bovine serum albumin. The complexes were divided 
into 50 µL aliquots and frozen at -80°C until use. 
2.3. Coupled PAT Assay 
 The HTS application of protein palmitoylation was 
recently described [13], but was adjusted for this study. The 
production of NADH was monitored with a Biotek Mx 
fluorimeter (Biotek, Winooski, VT) using 340 nm excitation/ 
465 nm emission. The 50 µl reaction contained 2 mM 2-
Oxoglutarate (α-ketoglutamic acid), 0.25 mM NAD+, 0.2 
mM Thiamine Pyrophosphate, 0.5 µg of purified 6xHIS-
Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM dithiothreitol, 8 mU 
2-oxogluarate dehydrogenase (α-ketoglutarate dehydro-
genase), 50 mM sodium phosphate, pH 6.8, and 0 - 100 µM 
inhibitor in 5% DMF. The reaction was initiated by the 
addition of 40 μM palmitoyl-CoA and monitored for 30 mins 
at 30°C. The first 10 mins of the reaction was analyzed to 
determine the initial rates of CoASH release. The PAT 
specific activity was determined from a standard curve of 
NADH production with different CoASH amounts. In these 
reactions, CoASH was added to the standard PAT reaction 
mixture (without Erf2/Erf4 complex or palmitoyl-CoA) and 
the reaction was allowed to proceed to equilibrium before 
fluorescence was measured. 
2.4. Scaffold Ranking Library 
 The scaffold ranking library contains one sample for each 
of the 68 positional scanning libraries tested. Each of these 
samples contains an approximate equal molar amount of 
each compound in that library. So, for example, the sample 
2160 in the scaffold ranking library contains 45,864 
compounds in approximately equal molar amounts. These 
samples can be prepared by mixing the cleaved products of 
the complete positional scanning library, as was the case for 
sample 2160, or they can be synthesized directly as a single 
mixture [12, 17]. Refer to supplemental Material for a 
thorough description of the synthesis of the scaffold ranking 
library and subsequent individual compounds. 
2.5. Positional Scanning Library 2160 
 Positional scanning library 2160 was synthesized using 
the scheme described in Fig. (S1). The positional scanning 
library incorporates both individual and mixtures of amino 
acids (R2) and carboxylic acid (R1 and R3). The synthetic 
technique facilitates the generation of information regarding 
the likely activity of individual compounds from the 
screening of the library [11, 18, 19]. Equimolar isokinetic 
ratios have been previously determined and calculated for 
each of the amino and carboxylic acids utilized for the 
respective mixtures [17, 20]. The bis-piperazine library 2160 
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has a total diversity of 45,864 compounds (42x26x42= 
45,864). The R1 and R3 positions as shown in Fig. (S1) each 
consist of 42 carboxylic acids and the R2 position contains 
26 amino acids. 
2.6. BODIPY®-C12:0 Autopalmitoylation Assay 
 BODIPY®-C12:0-CoA (40 µM final, unless specified 
otherwise) was added to a 50 µl reaction containing 
approximately 0.5 µg enzyme (6xHIS-Erf2/FLAG-Erf4) and 
100 µM inhibitors in 5% DMF in 50 mM sodium phosphate 
buffer, pH 6.8. The reactions were incubated 10 mins with 
inhibitor, and then the reaction was initiated with the 
addition of BODIPY®-C12:0-CoA, and incubated 15 mins at 
30°C. The reaction was terminated by the addition of 5x 
non-reducing protein loading buffer. Each reaction was 
heated at 65°C for three mins and then subjected to SDS-
PAGE (12%). The gel was washed three times in ddH2O and 
visualized on the Typhoon 9410 Variable Mode Imager (GE 
Healthcare, Piscataway, NJ) for BODIPY® fluorescence (ex. 
488 nm/em. 532 nm) to visualize co-migration of the 
BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4. The amount 
of 6xHIS-Erf2/FLAG-Erf4 was determined empirically using 
SDS-PAGE analysis under reducing conditions against a 
standard curve of bovine serum albumin. 
2.7. Growth Inhibition Assay 
 The in vivo effect of the inhibitors on Ras2 palmitoylation 
was investigated by comparing the growth of S. cerevisiae 
strains previously described for our complementation assay 
[16]. Briefly, the cells contain a defective allele of RAS2 that is 
balanced by an episomal copy of RAS2 linked to URA3. Under 
these conditions, the yeast strain cannot grow unless the 
episomal copy of RAS2 is palmitoylated. Varying concentrat-
ions of the inhibitors were added to 200 µl volumes of the yeast 
cells at an OD600 between 0.8 and 1.2 in a 96-well plate format. 
The OD600 was observed every 30 mins for 24 hrs and EC50 
values were determined by graphing rate of growth against 
concentration of inhibitor for each inhibitor. 
2.8. Yeast Cell Spot Assay 
 Following 24 hrs incubation with varying concentrations 
of the inhibitors in 1% DMF, S. cerevisiae strains RJY1941 
and RJY1942 were then diluted 1/100, and spotted onto SC-
Ura plates with 2% glucose. Cytotoxicity data was obtained 
by detecting the colony growth, following 48 hrs incubation 
at 30°C, with white light detection on the Bio-Rad Molecular 
Imager® ChemiDocTM XRS+ (Hercules, CA) and performing 
densitometry with Bio-Rad ImageLabTM software (Hercules, 
CA). Triplicate reactions were plated in triplicate. Values 
were normalized to vehicle control (1% DMF) for each plate, 
and then the averages of each reaction were compared for 
statistical analysis. 
3. RESULTS 
3.1. Inhibition of Erf2 Autopalmitoylation using a 
Fluorescence-Based Coupled Assay 
 The identification of palmitoylation inhibitors has been 
hampered by the lack of assays amenable to high throughout 
screening applications. Previously, we validated an assay 
that monitors the rate of autopalmitoylation by measuring the 
production of CoASH generated from the reduction of 
palmitoyl-CoA [13]. This assay has a Z'-value of 0.87 [13]. 
The intention of this assay is to couple the amount of 
CoASH formed (and hence, enzyme:palmitoyl intermediate 
formed) to the production of NADH, which is fluorescent. 
This assay can be used to monitor autopalmitoylation in real 
time or as an end point assay, thus providing flexibility when 
screening small molecule compounds. Compounds with 
internal fluorescence or that affect the assay components are 
easily identified and excluded, allowing for the rapid 
identification of the compounds that inhibit or activate PAT 
autopalmitoylation activity. 
 As an initial step in our screening campaign, we 
interrogated a scaffold ranking library developed by the 
Torrey Pines Institute for Molecular Studies [11-13]. This 
strategy allows for the evaluation of >30 million synthetic 
compounds while screening exponentially fewer reactions. 
This is achieved by organizing a large number of chemically 
diverse compounds into 68 core scaffolds. Each scaffold 
contains between 2,000 to 700,000 unique compounds at 
approximately equal molar concentrations. It is predicted 
that structural similarities will dictate additive effects 
increasing the chance that individual modulators will be 
detected despite being between nanomolar to sub-nanomolar 
concentrations [12, 21]. The vast number of structurally 
similar compounds in each scaffold library sample increases 
the probability of identifying a compound with useful 
chemical characteristics and properties [22]. Fig. (1) 
highlights a flow diagram of the stages involved in the 
identification and optimization of the compounds. We first 
screened the 68 scaffolds to determine the optimal scaffold 
structure (Fig. 1A). Once identified, positional scanning 
libraries of the lead scaffolds, which are organized by R-
groups at each position around a given scaffold, are screened 
(Fig. 1B). This allows for the prediction of optimal R-groups 
for each position on the core scaffold (Fig. 1C). Based on the 
optimized scaffold and knowledge of the active R-groups, 
individual compounds can be designed and synthesized to 
determine the positional effects of the R-groups on activity 
(Fig. 1D). Finally, based on the level of inhibition, we 
selected a subset of lead compounds for further analysis (Fig. 
1E). This approach allows us to expedite the screening 
process of millions of compounds and to generate structure 
activity relationship (SAR) information earlier in the 
screening process. A description of the library construction 
and use can be found in recent reviews [11, 22-25]. 
3.2. Scaffold Ranking of the Erf2 Autopalmitoylation 
Inhibitors 
 We screened 68 scaffold ranking samples, each at a 
concentration of 100 μg/ml/scaffold (Fig. 2). Each scaffold 
sample was pre-incubated with Erf2 enzyme for 10 mins at 
30°C before initiating the reaction with the addition of 
palmitoyl-CoA. We monitored the production of CoASH for 
30 mins to ensure a linear response over time and determined 
the rate of the reaction for each scaffold sample. Incubation 
of the enzyme with several of the scaffold samples resulted 
in a reduction in the production of CoASH. As an initial 
criterion, we defined inhibition as a reduction in activity 
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greater than three standard deviations from the mean activity 
value. We identified eight of the scaffold libraries that fit this 
definition. Scaffolds 2103, 2236, 2165, 2220, 1509, 2160, 
2228, and 2221 caused at least a 50% reduction in Erf2 
autopalmitoylation activity. In contrast, scaffold 1509 
appeared to react with the assay components and was 
excluded from further analysis. The data from two of the 
scaffolds, 2165 and 2228, were not reproducible and these 
scaffolds were also excluded (data not shown). We 
established a baseline of inhibition using boiled and 
catalytically inactive enzyme. 
 The remaining 5 scaffolds were then screened for dose 
responsiveness at 200 μg/ml, 100 μg/ml, and 50 μg/ml (Fig. 
3A). Similar to the dosage response observed for 2-BP, three 
of the five scaffold libraries (2160, 2220 and 2236) 
demonstrated some degree of dosage response at these 
concentrations. Interestingly, these three scaffold libraries 
included a piperazine-analog feature. Scaffold 2220 is a 
piperazine, scaffold 2221 is a pyrolidine piperazine, and 
scaffold 2160 is a bis-cyclic piperazine (Fig. 3B). Of these, 
scaffold 2160 reproducibly decreased PAT activity in a dose 
dependent fashion to the greatest extent. Structurally, 
scaffold 2160 has a core bis-cyclic piperazine with three R-
groups, and a total diversity of 45864 compounds (Fig. 1B). 
 The 45864 compounds in scaffold 2160 were synthesized 
into 110 mixture samples organized by R-group (Fig. 1C). 
At position R1 and R3 there were 42 functionalities derived 
from different carboxylic acids (samples 2160.001-2160.042 
and 2160.069-2160.110, respectively), and 26 derived from 
amino acids at the R2 position (samples 2160.043-
2160.068). Thus, samples organized by R1 or R3 positions 
contain 1092 (42 x 26) compounds per sample, and samples 
organized by the R2 position contain 1764 (42 x 42) 
compounds per sample. The 110 samples were screened for 
inhibition of Erf2 autopalmitoylation at a concentration of 
100 μg/ml. Ninety-nine of the 110 mixture samples had no 
significant effect on Erf2 autopalmitoylation, where 25% 
inhibition was considered the cutoff for significance (data 
not shown). Four functional groups at position R1, three at 
position R2 and four at position R3, resulted in a greater than 
25% reduction and were selected for synthesis of 48 
individual compounds. 
 
 
Fig. (1). Schematic representation of the chemical library screen. A, The Torrey Pines Institute for Molecular Studies scaffold library 
approach starts with >30 million compounds that are organized by 68 core scaffolds with 2,000 – 700,000 different compounds per scaffold. 
B, A lead scaffold is selected for the positional scanning screen. C, All of the compounds in the positional scanning screen contain the same 
core scaffold structure and are organized by the R-groups at each position. Each of the plates contains the same compounds organized by the 
different R-group position to determine if a particular functional group is optimal at one of the positions. The positional scanning library 
screened in this study contained 110 positional scanning samples that each comprise of 1,000 – 2,000 individual compounds for a total 
diversity of 45864 individual compounds. D, The selectivity for the different R-groups is predicted for each position based on the positional 
scanning results. In this study, 48 individual compounds were synthesized. E, Of the 48 individual compounds synthesized ten were selected 
for further analysis in additional assays. In total 226 samples were tested; 68 Scaffolds, 110 positional scanning scaffolds, 48 individual 
compounds.  
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Fig. (2). Results of the screen for inhibition of Erf2 auto-palmitoylation. The scaffold ranking library screen of 68 scaffolds was screened 
at 100 μg/ml, and the average velocity of Erf2 auto-palmitoylation of three reactions is presented as a fraction of vehicle control (1% DMF). 
The velocity of Erf2 auto-palmitoylation was detected as an increase in fluorescence over time. No effect on Erf2 auto-palmitoylation would 
fall at 1 arbitrary unit (solid line). Scaffolds that resulted in a reduction in Erf2 auto-palmitoylation 3 standard deviations (dashed line) or 
greater were considered hits of this assay. A heat inactivated Erf2 (Boiled) and a catalytically inactive mutant of Erf2 (C203S) represent 
baseline activity in this assay. 100 μM 2-BP is a control for inhibition of Erf2 auto-palmitoylation. 
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3.3. Individual Compounds Screened for Inhibition of 
Erf2 Autopalmitoylation 
 The 48 compounds were screened with five of the hits 
from the positional scanning samples (2160.066, 2160.082, 
2160.001, 2160.065, and 2160.108) and the complete 2160-
scaffold sample (Fig. 4). Scaffold 2160 and the positional 
scanning samples inhibited Erf2 autopalmitoylation 
consistent with prior screens and demonstrated that as the 
complexity decreased from 45864 compounds (scaffold 
2160), to 1000-2000 compounds (positional scanning), and 
finally, to individual compounds, there was a concomitant 
increase in the inhibition of Erf2 autopalmitoylation (Fig. 4). 
As an additional control, we included non-optimized 
compounds (compounds 49-54), which were designed with 
side groups that did not pass the original cutoff in the 
positional scanning screen. These compounds, as anticipated, 
demonstrated poor inhibition of Erf2 autopalmitoylation in 
comparison to the compounds whose design was based on  
 
the positional scanning results. We determined the inhibition 
constant (Ki) for the top ten compounds by determining the 
rate of autopalmitoylation activity for varying amounts of 
inhibitor compound (data not shown). The autopalmitoylat-
ion inhibition constants ranged from ~63-142 µM for the ten 
compounds identified in this study, and 59 μM for 2-BP 
(Fig. 5, right panel). 
 There did not appear to be a preference within the top 40 
compounds for the R2 position amongst the four 
possibilities; hydroxybenzyl, phenyl, and (S or R) 
naphthymethyl groups (Fig. 5). There were three possibilities 
at the R3 position, and it was at this position that the greatest 
preference was observed. 2-(4-isobutyl-phenyl)-propyl was 
the optimal group at this position and is present in seven of 
the top ten hits. 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl is 
the most prevalent in the next 15, and the completely 
aliphatic functional group, adamantan-1-yl-methyl, is in this 
position for a majority of the remaining top 40 individual  
 
 
Fig. (3). Inhibition of Erf2 auto-palmitoylation by varying the concentration of library samples. A, The velocity of Erf2 auto-
palmitoylation on the coupled assay with the lead scaffold ranking library samples (2160, 2220, 2236, 2221, 2103). The velocity of Erf2 
auto-palmitoylation was detected as an increase in fluorescence over time. Average values of three reactions are presented as a fraction of 
vehicle control (1% DMF) +/- standard deviation. Samples were screened at 50 μg/ml (dark grey bars), 100 μg/ml (light grey bars), and 200 
μg/ml (white bars) compared to 2-BP at 50 μM (dark grey bars), 100 μM (light grey bars), and 200 μM (white bars). A reaction lacking Erf2 
( - ) represents baseline activity in the assay. B, Structures of lead scaffolds and 2-Bromopalmitic Acid. Positions for varying functional 
groups are denoted by R1-R4. Scaffold 2160 contains three R-group positions, scaffolds 2220, 2221, and 2103 each contain two R-group 
positions, and scaffold 2236 contains four R-group positions. 
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Fig. (4). Inhibition of Erf2 auto-palmitoylation by individual compounds derived from the 2160 scaffold. Relative velocity of Erf2 
auto-palmitoylation with 100 μg/ml of optimized individual compounds (1-48), non-specific individual compounds (49-54), positional 
scanning samples (2160.066, 2160.082, 2160.001, 2160.065, and 2160.108), and lead scaffold ranking library sample (2160). The velocity of 
Erf2 auto-palmitoylation was detected as an increase in fluorescence over time. Average values of three reactions presented as a fraction of 
vehicle control (1% DMF) +/- standard deviation. A reaction lacking Erf2 ( - ) represents baseline activity in the assay. 50 μM 2-BP is a 
control for inhibition of Erf2 auto-palmitoylation. 
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compounds. The R1 position also showed similar specificity 
for the functional groups utilized in the individual 
compounds. At the R1 position, nearly all of the top 30 
compounds have either 2-(3,5-bis-trifluoromethyl-phenyl)-
ethyl or 2-(4-isobutyl-phenyl)-propyl, the same top two 
groups for the R3 position. A >50% reduction in Erf2 
autopalmitoylation was observed for most of the optimized 
individual compounds, but only the top ten were selected for 
additional analysis. 
 To determine if the ten compounds identified in this 
study were inhibiting autopalmitoylation, and not targeting 
hydrolysis of the enzyme, steady-state autopalmitoylation 
was evaluated at 100 μM of each compound compared to 
100 μM 2-BP and DMF (vehicle) alone. This was performed 
in a gel-based reaction using BODIPY®-C12-CoA [26]. The 
reactions were separated by SDS-PAGE and steady-state 
autopalmitoylation was determined by the relative BODIPY® 
fluorophore that co-migrated with Erf2, demonstrating that 
Erf2 was acylated by BODIPY®-C12 [26]. At 100 μM, the 
ten compounds each resulted in a 50% or greater decrease in 
steady-state Erf2 autopalmitoylation compared to vehicle 
alone. From these screens we observed a decrease in 
BODIPY® fluorescence at the apparent  
 
molecular weight of Erf2. This does not confirm that the 
inhibitors are directly interacting with Erf2 as they could be 
reducing the stability of the Erf2-Erf4 complex. Taking that 
into consideration, all of the compounds inhibited 
autopalmitoylation to either an equal or greater extent 
compared to 2-BP (Fig. 6). Dose response curves of steady-
state autopalmitoylation activity were examined to determine 
the Ki for each compound (data not shown). The steady-state 
autopalmitoylation inhibition constants ranged from ~34-72 
µM for the ten compounds identified in this study, and 79 
μM for 2-BP (Fig. 5, right panel). 
3.4. Compounds 13 and 25 Competitively Inhibit Erf2 
Autopalmitoylation 
 The potential for the symmetry of the compounds to play 
a role in their efficacy is of interest as the same functional 
groups were identified for the top two leads at both positions 
R1 and R3, and positions R1 and R3 are located on nitrogens 
of the opposing piperazine ring structures on the bis-cyclic 
piperazine scaffold. To interrogate this, the compounds 13, 
14, and 25 were selected for further analysis as they 
represent a unique set of three compounds where all three 
have the same functional group at position R1, compound 13  
 
 
Fig. (5). Structure of the scaffold 2160 derived compounds. The structure for scaffold 2160, bis-cyclic piperazine has three R-group 
positions designated R1, R2, and R3. The lead functional groups are 2-(4-Isobutyl-phenyl)-propyl (i), 2-(3,5-bis-trifluoromethyl-phenyl)-
ethyl (ii), 4-tert-butyl-cyclohexyl-methyl (iii), S-4-hydroxybenzyl (iv), S-phenyl (v), S-2-naphthylmethyl (vI), and adamantan-1-yl-methyl 
(vii). The curved lines on the functional group structures designate where they will share a bond with the core scaffold. Positions for each 
functional group are described in the right panel. Ki values for the fluorescence-based coupled assay of the rate of Erf2 autopalmitoylation 
(FCA) and the orthogonal gel-based assay of steady-state Erf2 autopalmitoylation (GBA) are listed for each compound (14, 13, 25, 28, 34, 
19, 22, 43, 27, and 30) as well as EC50 values obtained from the growth curve experiments in S. cerevisiae RJY1942 (Sens.) and RJY1941 
(cont.). All values are represented in M concentrations. The increased detection sensitivity of the FCA allowed for the determination of 
standard deviation. 
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Fig. (6). Inhibition of Erf2 auto-palmitoylation measured by a 
gel-based assay. An orthogonal screen of steady-state Erf2 auto-
palmitoylation with 100 μM of each of the ten individual 
compounds (43, 27, 19, 13, 22, 34, 14, 25, 30, and 28) was 
separated by SDS-PAGE. The average relative BODIPY® 
fluorescence from three reactions that co-migrated with Erf2 is 
presented as a fraction of vehicle control (V; 5% DMF) +/- standard 
deviation. A reaction lacking Erf2 ( - ) represents baseline activity 
in the assay. 100 μM 2-BP is a control for inhibition of Erf2 steady-
state auto-palmitoylation. 
has the lead functional group, 2-(3,5-bis-trifluoromethyl-
phenyl)-ethyl, at positions R1 and R3, compound 14 also has 
2-(3,5-bis-trifluoromethyl-phenyl)-ethyl at position R1, but 
has the second lead functional group, 4-tert-butyl-cyclo-
hexyl-methyl at the R3 position, and compound 25 has the 
reverse; 4-tert-butyl-cyclohexyl-methyl at the R1 position  
 
and 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl at position R3. 
Thus, compound 13 represents a compound with symmetry 
and compounds 14 and 25 are complementary non-
symmetrical representatives with the same alternative 
functional group at opposite positions. Of the ten lead 
compounds, these three are the only ones to satisfy this 
scenario. 
 To first elucidate if these compounds were 
mechanistically different from 2-BP, we performed inhibitor 
titrations, varying the amount of compound 13 (or compound 
25) and palmitoyl-CoA. Over the concentration range tested, 
compounds 13 and 25, increasing inhibitor concentration 
increased the KM (palmitoyl-CoA) of the reaction while 
having little effect on the VMAX. (Fig. 7). It was not possible 
to increase palmitoyl-CoA concentrations above 80 µM due 
to the CMC. The KM and VMAX values calculated are 
summarized in Table 1. 
 The mode of inhibition was also explored for effects on 
steady-state autopalmitoylation using the gel-based 
orthogonal assay. Compound 13 exhibits a greater dosage 
response for Erf2 autopalmitoylation inhibition at lower 
BODIPY®-C12-CoA concentrations rather than at higher 
BODIPY®-C12-CoA concentrations, supporting that 
compound 13 is acting competitively with BODIPY®-C12-
CoA (Fig. 8). Conversely, 2-BP has been previously 
demonstrated as an uncompetitive or mixed inhibitor of Erf2 
autopalmitoylation [13], demonstrating that compounds 13 
and 25 utilize a different inhibitory mechanism compared to 
2-BP. Thus, we have identified a new class of palmitoylation 
inhibitors that are structurally distinct and utilize a mode of 
action different from the currently used palmitoylation 
inhibitor, 2-BP. 
 
Fig. (7). Michaelis-Menten plots for Compounds 13 and 25, and 2-BP. The velocity of Erf2 auto-palmitoylation as altered by the addition 
of the inhibitors at 100 μM (empty diamonds), 50 μM (filled squares), 25 μM (empty triangles), and vehicle control (1% DMF; filled circles) 
for compounds 13 and 25, and 2-BP. The velocity of Erf2 auto-palmitoylation was detected as an increase in fluorescence over time. VMAX is 
the maximum velocity of the reaction, and KM is the substrate concentration that allows the reaction to reach a velocity that is 50% of the 
VMAX. On the Michaelis-Menton Plot, a competitive inhibitor would increase KM without altering VMAX, whereas an uncompetitive inhibitor 
would result in a decrease of VMAX without altering the KM of the reaction. 
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Table 1. The effect of varying the concentration of 
Compounds 13 and 25, and 2-BP on the Km and 
Vmax for the Palmitoyl-CoA substrate. 
 
Compound 13 KM VMAX 
R2 
(μM) (μM) (μM) 
0 3 +/- 1 210 +/- 11 0.9 
25 11 +/- 3 243 +/- 20 0.87 
50 38 +/- 6 354 +/- 26 0.97 
100 145 +/- 30 631 +/- 94 0.98 
Compound 25 KM VMAX 
R2 
(μM) (μM) (μM) 
0 3 +/- 1 296 +/- 17 0.88 
25 11 +/-3 307 +/- 30 0.83 
50 23 +/- 6 344 +/- 34 0.91 
100 79 +/- 15 542 +/- 60 0.98 
2-BP KM VMAX 
R2
(μM) (μM) (μM) 
0 4 +/- 1 222 +/-7 0.96 
25 2 +/-1 160 +/-5 0.95 
50 10 +/-6 126 +/- 23 0.53 
100 14 +/- 7 51 +/-8 0.71 
 
 
Fig. (8). Inhibition of palmitoyl-CoA concentration dependent 
palmitoylation of Erf2 by Compound 13. Orthogonal screen of 
steady-state Erf2 auto-palmitoylation with compound 13 at 25 μM 
(dark grey bars), 50 μM (light grey bars) and 100 μM (white bars) 
was separated by SDS-PAGE. The average relative BODIPY® 
fluorescence from three reactions that co-migrated with Erf2 is 
presented as a fraction of vehicle control (VC; 5% DMF) for each 
concentration of BODIPY®-C12-CoA +/- standard deviation. A 
reaction lacking Erf2 ( - ) represents baseline activity in the assay. 
Prior experiments in this study used 100 μM Compound 13 with 40 
μM BODIPY®-C12-CoA. 
3.5. Inhibition of Ras-Dependent Growth in a 
Palmitoylation-Sensitive S. cerevisiae Strain 
 To examine the inhibition of Ras palmitoylation in vivo, 
we utilized two strains of S. cerevisiae. The yeast strain 
RJY1942 (palmitoylation sensitive) requires Ras2 
palmitoylation for viability [16]. The isogenic wild type 
control yeast strain (RJY1941) is not dependent on Ras2 
palmitoylation for viability. The growth of both strains was 
monitored in the presence (or absence) of our inhibitors 
every 30 mins for 24 hrs. EC50 values were calculated using 
GraphPad Prism® (La Jolla, CA) to extrapolate the effective 
concentration of each inhibitor that caused a 50% reduction 
in growth (Fig. 9). EC50 values ranged from 2 μM to 7.5 μM 
in the sensitive strain, compared to 12.5 μM for 2-BP in the 
sensitive strain. Compounds 13, 25, and 2-BP show a modest 
selectivity for the sensitive strain, RJY1942, over the control 
strain, RJY1941, resulting in a 2-fold greater EC50 value in 
the control strain as compared to the sensitive strain (values 
listed in Fig. 5, right panel). It is not clear at this time why 
only compounds 13 and 25 exhibit selectivity in the cell 
based assay, whereas there is the others inhibit the purified 
enzyme to a similar extent. Additional work is needed to 
determine the mechanism of growth inhibition and 
selectivity of these compounds. 
 We next compared the ability of either strain to grow 
following the 24 hrs incubation with Compounds 13, 14, or 
25. Serial dilutions of RJY1941 and RJY1942 were spotted 
on agar plates following incubation for 24 hrs with varying 
inhibitor concentrations. Compounds 13, 14, and 25 comple-
tely inhibited growth of RJY1941 (control) at 20 µM, but 
had no detectable effect at lower concentrations (Fig. 10). 
Conversely, compound 13 inhibited (100%) the growth of 
RJY1942 (sensitized) at 5 µM. Compound 25 also inhibited 
at 5 μM, albeit at approximately 90% of that observed for 
compound 13 for the sensitized strain. Compound 14 
demonstrated partial inhibition (approximately 10%) at 5 
µM, however, total inhibition could be observed for the 
sensitized strain at higher inhibitor concentrations. 2-BP did 
not inhibit, most likely due to poor permeability of 2-BP on 
solid yeast medium. 
4. DISCUSSION 
 Protein S-palmitoylation is a posttranslational modification 
that regulates the subcellular localization and activity of a 
diverse set of signaling and structural proteins. Dysregulation 
of protein palmitoylation has been linked to a number of 
diseases. Examples include up-regulation of zDHHC9 in 
colorectal cancer [27] and down-regulation of zDHHC9 in 
leukemogenesis [28]; zDHHC3/GODZ is linked to cervical 
cancer [29] and zDHHC2 mutations have been found in 
several colorectal cancers [30]. The importance of 
palmitoylation in physiology and pathophysiology suggests 
that modulators of catalyzed palmitoyl transfer may play a 
role in disease treatment. The availability of PAT inhibitors 
is very limited. 2-Bromo-palmitate (2-BP), cerulenin, and 
tunicamycin have been reported to inhibit palmitoylation [8, 
31-33], but 2-BP is now known to be highly promiscuous, 
with no preference for CoA-dependent enzymes, including 
zDHHC PATs [9]. Similarly, cerulenin and tunicamycin 
inhibit palmitoylation within cells but also inhibit other 
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cellular process including fatty acid synthesis [34] and N-
glycosylation [35], respectively. In addition, there are few 
assays available that can measure palmitoylation [3, 13] in a 
high throughput platform. There is therefore a need to 
establish methods to identify small molecule PAT inhibitors 
for use in vitro and in vivo. 
 The current lack of high affinity, specific inhibitors is 
due in part to difficulties purifying biochemical quantities of 
PATs, limited information on the enzymatic mechanism and 
the lack of a 3D crystal structure. We have developed 
methods to purify stable, active zDHHC PATs, along with a  
 
validated HTS method to identify inhibitors. This has 
allowed the search for chemical modulators of PAT enzymes 
using HTS coupled with counter screens, orthogonal 
validation and cell-based assays, to characterize and analyze 
candidate inhibitors. With these tools in hand we are able to 
identify compounds that regulate the Ras PAT, Erf2. 
 Through the use of a scaffold ranking approach to screen 
for novel inhibitors of Erf2 autopalmitoylation, we have 
identified a group of inhibitors based on the bis-cyclic 
piperazine backbone. Piperazine analogues have already 
been demonstrated to be effective drug-like compounds.  
 
 
Fig. (9). Inhibition of Ras palmitoylation-sensitized yeast. The EC50 for each of the individual compounds was established by graphing the 
logarithmic growth of S. cerevisiae strain, RJY1941 (solid lines and solid circles) and RJY1942 (hashed lines and open circles), versus the 
concentration of each compound. The curves were used to estimate the EC50 values are presented for 2-BP and the ten compounds identified 
in this study. Values were normalized to visually compare relative log of the growth rate of each compound and 2-BP. 
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Fig. (10). Compounds 13, 25, and 14 inhibit palmitoylated Ras-
dependent growth in yeast. A representative (n=3) spot assay of 
cytotoxic effects in wild type (RJY1941) S. cerevisiae is compared 
to that of the palmitoylation-dependent (RJY1942) strain. Liquid 
cultures containing the shown inhibitors were spotted onto selective 
media and incubated at 30°C for 3 days. The concentrations used in 
the liquid cultures for compounds 13, 25, 14 and 2-BP were 2.5 
μM, 5 μM, 10 μM, and 20 μM in 1% DMF. 
They are currently used as pharmaceutical modulators of 
GPCR activity and piperazine-like compounds and analogs 
are also used as pharmaceuticals to treat cancer, behavioral 
disorders, and insomnia (e.g., imatinib, quetiapine, and 
eszopiclone) [36-38]. To further explore their specificity for 
use as modulators of palmitoylation, there is ongoing work 
to address any inhibitor:enzyme specificity issues by 
establishing if the inhibitors identified in this study act 
specifically on Erf2-dependent palmitoylation, or if they act 
on one or more of the other PAT enzymes. Further analysis 
will be needed to validate these compounds as pan inhibitors 
of palmitoylation, which would be beneficial over 2-BP due 
to the extent of non-specific inhibition that occurs with the 
use of 2-BP. Specific inhibitors of Erf2 and its human 
homolog, zDHHC9, will be beneficial for anti-cancer drug 
therapy interventions. Understanding how the different 
functional groups lend to their activity and specificity is key 
to further optimize these compounds. The compounds best 
align with the Ki and EC50 values from the respective screens 
when they were organized by the R3 position with 
consideration of the R1 and R2 positions (Fig. 5). Of the 
functionalities used at the R1 and R3 positions both 2-(4-
Isobutyl-phenyl)-propyl and 2-(3,5-bis-trifluoromethyl-
phenyl)-ethyl were the most preferential for both positions. 
This, along with the apparent symmetry of bis-piperazine, 
suggests that perhaps these compounds can act as 
symmetrical entities. The lack of preference, other than for 
an aromatic group, in the R2 position supports this notion. 
CONCLUSION 
 We have identified a novel class of bis-cyclic piperazines 
that inhibit Erf2 autopalmitoylation utilizing a fluorescence-
based coupled assay, orthogonal gel-based assay and cell 
growth assay. A subset of these bis-cyclic piperazines shows 
Ras-dependent inhibition of yeast cells in vivo. 
 
ABBREVIATIONS 
2-BP = 2-bromopalmitic acid 
APT = Acyl protein thioesterase 
CoA = Coenzyme A 
DCM = Dichloromethane 
DIC = Diisopropylcarbodiide 
DIEA = Diisopropylethylamine 
DMF = Dimethylformamide 
HOBt = 1-hydroxybenzotriazole hydrate 
HTS = High throughput screen 
MBHA = p-Methylbenzyhydrylamine 
MEOH = Methanol 
PAT = Protein acyl transferase 
TFA = Trifluoroacetic acid 
THF = Tetrahydrofuran 
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